Clinical Impact of Circulating MiR-18a in Plasma of Patients with Oesophageal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Apr 13

PMID 23579215

Citations 62

Authors

S Hirajima

S Komatsu

D Ichikawa

H Takeshita

H Konishi

A Shiozaki

R Morimura

M Tsujiura

H Nagata

T Kawaguchi

T Arita

T Kubota

H Fujiwara

K Okamoto

E Otsuji

Affiliations

Soon will be listed here.

Abstract

Background: Several recent studies demonstrated that microRNAs are stably detectable in plasma/serum. We tested whether miR-18a, which is located in the miR-17-92 cluster and reported to be highly expressed in tissues of oesophageal squamous cell carcinoma (ESCC), served as a plasma biomarker in patients with ESCC.

Methods: This study was divided into three steps: (1) confirmation of higher miR-18a levels in primary ESCC tissues and cell lines than normal ESCC tissues and a human fibroblast cell line. (2) Evaluation of the plasma miR-18a assay using quantitative RT-PCR by comparing results from 106 consecutive patients with ESCC and 54 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in patients with ESCC.

Results: (1) Expression of miR-18a was significantly higher in ESCC tissues (P=0.0020) and ESCC cell lines (P=0.0121) than normal tissues and fibroblasts. (2) Plasma concentrations of miR-18a were significantly higher in ESCC patients than healthy volunteers (P<0.0001; ESCC patients vs healthy volunteers (mean±s.d.): 11.77±13.45 vs 0.73±0.54 amol μl(-1)). The value of the area under the receiver-operating characteristic (ROC) curve (AUC) was 0.9449. Furthermore, the ROC curves to detect early ESCC such as pTis-1 and pStage0-I showed AUCs of 0.9479 and 0.9642, respectively. (3) Plasma levels of miR-18a were significantly lower in postoperative samples than preoperative samples (P=0.0076).

Conclusion: Plasma miR-18a may be a very useful biomarker for cancer detection and the monitoring of tumour dynamics in patients with ESCC.

Citing Articles

Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.

Imamura T, Komatsu S, Nishibeppu K, Kiuchi J, Ohashi T, Konishi H BMC Cancer. 2024; 24(1):907.

PMID: 39069624 PMC: 11283702. DOI: 10.1186/s12885-024-12676-x.

Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.

Kamiya H, Komatsu S, Takashima Y, Ishida R, Arakawa H, Nishibeppu K Br J Cancer. 2023; 130(4):671-681.

PMID: 38148376 PMC: 10876550. DOI: 10.1038/s41416-023-02532-3.

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V Int J Mol Sci. 2022; 23(15).

PMID: 35897831 PMC: 9367895. DOI: 10.3390/ijms23158257.

MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients.

Kahng D, Kim G, Park S, Kim S, Lee M, Lee B J Korean Med Sci. 2022; 37(24):e197.

PMID: 35726148 PMC: 9247724. DOI: 10.3346/jkms.2022.37.e197.

Depletion of tumor suppressor miRNA-148a in plasma relates to tumor progression and poor outcomes in gastric cancer.

Komatsu S, Imamura T, Kiuchi J, Takashima Y, Kamiya H, Ohashi T Am J Cancer Res. 2022; 11(12):6133-6146.

PMID: 35018247 PMC: 8727801.

References

Leivonen S, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K . Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009; 28(44):3926-36. DOI: 10.1038/onc.2009.241. View

Woods K, Thomson J, Hammond S . Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2006; 282(4):2130-4. DOI: 10.1074/jbc.C600252200. View

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

He L, Thomson J, Hemann M, Hernando-Monge E, Mu D, Goodson S . A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-33. PMC: 4599349. DOI: 10.1038/nature03552. View

Ayala de la Pena F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R . Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011; 286(23):20778-87. PMC: 3121487. DOI: 10.1074/jbc.M110.198069. View

Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M . Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2011; 5(3):492-497. PMC: 4186243. DOI: 10.1158/1940-6207.CAPR-11-0370. View

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

Ng E, Chong W, Jin H, Lam E, Shin V, Yu J . Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-81. DOI: 10.1136/gut.2008.167817. View

10.

Li T, Chen J, Fu X, Yang S, Zhang Z, Chen K . microRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep. 2011; 25(5):1353-63. DOI: 10.3892/or.2011.1204. View

11.

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View

12.

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

13.

Ichikawa D, Komatsu S, Konishi H, Otsuji E . Circulating microRNA in digestive tract cancers. Gastroenterology. 2012; 142(5):1074-1078.e1. DOI: 10.1053/j.gastro.2012.03.008. View

14.

Liu M, Wang Z, Yang S, Zhang W, He S, Hu C . TNF-α is a novel target of miR-19a. Int J Oncol. 2011; 38(4):1013-22. DOI: 10.3892/ijo.2011.924. View

15.

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

16.

Hollstein M, Metcalf R, Welsh J, Montesano R, Harris C . Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990; 87(24):9958-61. PMC: 55293. DOI: 10.1073/pnas.87.24.9958. View

17.

Zhang C, Wang C, Chen X, Yang C, Li K, Wang J . Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem. 2010; 56(12):1871-9. DOI: 10.1373/clinchem.2010.147553. View

18.

Zhu H, Fan G . Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011; 1(2):138-149. PMC: 3207246. View

19.

Hasselmann D, Rappl G, Tilgen W, Reinhold U . Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem. 2001; 47(8):1488-9. View

20.

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View